FDA Grants Breakthrough Therapy Designation to Rare Blood Disorder Treatment
January 4th 2018Officials with the FDA have granted breakthrough therapy designation to eltrombopag (Promacta, Novartis) for first-line use, in combination with standard immunosuppressive therapy, in patients with severe aplastic anemia.
Read More
Tetraphase Submits NDA for Investigational Drug for Complicated Intra-Abdominal Infections
January 3rd 2018Tetraphase Pharmaceuticals today announced submission of its new drug application (NDA) to the FDA for eravacycline, in IV form, for the treatment of complicated intra-abdominal infections (cIAI).
Read More